Request Free Sample ×
ReportInfographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

UK Dry Age Related Macular Degeneration Market

ID: MRFR/MED/43214-HCR
200 Pages
Vikita Thakur
Last Updated: April 06, 2026

UK Dry Age-Related Macular Degeneration (AMD) Market Research Report: Size, Share, Trend Analysis By Stage (early age-related macular degeneration, intermediate age-related macular degeneration, late age-related macular degeneration), By Age Group (above 75 years, above 60 years, above 40 years), By Diagnosis and Treatment (treatment, diagnosis), By Route of Administration (oral, injectables) and By End Userss (hospitals clinics, diagnostic centers, academic research institutes) - Growth Outlook & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

UK Dry Age Related Macular Degeneration Market Infographic
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
  2.   1.1 EXECUTIVE SUMMARY
  3.     1.1.1 Market Overview
  4.     1.1.2 Key Findings
  5.     1.1.3 Market Segmentation
  6.     1.1.4 Competitive Landscape
  7.     1.1.5 Challenges and Opportunities
  8.     1.1.6 Future Outlook
  9. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
  10.   2.1 MARKET INTRODUCTION
  11.     2.1.1 Definition
  12.     2.1.2 Scope of the study
  13.       2.1.2.1 Research Objective
  14.       2.1.2.2 Assumption
  15.       2.1.2.3 Limitations
  16.   2.2 RESEARCH METHODOLOGY
  17.     2.2.1 Overview
  18.     2.2.2 Data Mining
  19.     2.2.3 Secondary Research
  20.     2.2.4 Primary Research
  21.       2.2.4.1 Primary Interviews and Information Gathering Process
  22.       2.2.4.2 Breakdown of Primary Respondents
  23.     2.2.5 Forecasting Model
  24.     2.2.6 Market Size Estimation
  25.       2.2.6.1 Bottom-Up Approach
  26.       2.2.6.2 Top-Down Approach
  27.     2.2.7 Data Triangulation
  28.     2.2.8 Validation
  29. 3 SECTION III: QUALITATIVE ANALYSIS
  30.   3.1 MARKET DYNAMICS
  31.     3.1.1 Overview
  32.     3.1.2 Drivers
  33.     3.1.3 Restraints
  34.     3.1.4 Opportunities
  35.   3.2 MARKET FACTOR ANALYSIS
  36.     3.2.1 Value chain Analysis
  37.     3.2.2 Porter's Five Forces Analysis
  38.       3.2.2.1 Bargaining Power of Suppliers
  39.       3.2.2.2 Bargaining Power of Buyers
  40.       3.2.2.3 Threat of New Entrants
  41.       3.2.2.4 Threat of Substitutes
  42.       3.2.2.5 Intensity of Rivalry
  43.     3.2.3 COVID-19 Impact Analysis
  44.       3.2.3.1 Market Impact Analysis
  45.       3.2.3.2 Regional Impact
  46.       3.2.3.3 Opportunity and Threat Analysis
  47. 4 SECTION IV: QUANTITATIVE ANALYSIS
  48.   4.1 Healthcare, BY Disease Stage (USD Million)
  49.     4.1.1 Early Stage
  50.     4.1.2 Intermediate Stage
  51.     4.1.3 Late Stage
  52.   4.2 Healthcare, BY Treatment Type (USD Million)
  53.     4.2.1 Pharmacological Treatment
  54.     4.2.2 Surgical Intervention
  55.     4.2.3 Nutritional Supplements
  56.   4.3 Healthcare, BY Patient Demographics (USD Million)
  57.     4.3.1 Age Group
  58.     4.3.2 Gender
  59.     4.3.3 Socioeconomic Status
  60.   4.4 Healthcare, BY Healthcare Setting (USD Million)
  61.     4.4.1 Outpatient Clinics
  62.     4.4.2 Hospitals
  63.     4.4.3 Home Healthcare
  64.   4.5 Healthcare, BY Market Distribution Channel (USD Million)
  65.     4.5.1 Direct Sales
  66.     4.5.2 Online Sales
  67.     4.5.3 Pharmacies
  68. 5 SECTION V: COMPETITIVE ANALYSIS
  69.   5.1 Competitive Landscape
  70.     5.1.1 Overview
  71.     5.1.2 Competitive Analysis
  72.     5.1.3 Market share Analysis
  73.     5.1.4 Major Growth Strategy in the Healthcare
  74.     5.1.5 Competitive Benchmarking
  75.     5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  76.     5.1.7 Key developments and growth strategies
  77.       5.1.7.1 New Product Launch/Service Deployment
  78.       5.1.7.2 Merger & Acquisitions
  79.       5.1.7.3 Joint Ventures
  80.     5.1.8 Major Players Financial Matrix
  81.       5.1.8.1 Sales and Operating Income
  82.       5.1.8.2 Major Players R&D Expenditure. 2023
  83.   5.2 Company Profiles
  84.     5.2.1 Novartis AG (CH)
  85.       5.2.1.1 Financial Overview
  86.       5.2.1.2 Products Offered
  87.       5.2.1.3 Key Developments
  88.       5.2.1.4 SWOT Analysis
  89.       5.2.1.5 Key Strategies
  90.     5.2.2 Regeneron Pharmaceuticals Inc (US)
  91.       5.2.2.1 Financial Overview
  92.       5.2.2.2 Products Offered
  93.       5.2.2.3 Key Developments
  94.       5.2.2.4 SWOT Analysis
  95.       5.2.2.5 Key Strategies
  96.     5.2.3 Roche Holding AG (CH)
  97.       5.2.3.1 Financial Overview
  98.       5.2.3.2 Products Offered
  99.       5.2.3.3 Key Developments
  100.       5.2.3.4 SWOT Analysis
  101.       5.2.3.5 Key Strategies
  102.     5.2.4 Bayer AG (DE)
  103.       5.2.4.1 Financial Overview
  104.       5.2.4.2 Products Offered
  105.       5.2.4.3 Key Developments
  106.       5.2.4.4 SWOT Analysis
  107.       5.2.4.5 Key Strategies
  108.     5.2.5 Allergan PLC (IE)
  109.       5.2.5.1 Financial Overview
  110.       5.2.5.2 Products Offered
  111.       5.2.5.3 Key Developments
  112.       5.2.5.4 SWOT Analysis
  113.       5.2.5.5 Key Strategies
  114.     5.2.6 Apellis Pharmaceuticals Inc (US)
  115.       5.2.6.1 Financial Overview
  116.       5.2.6.2 Products Offered
  117.       5.2.6.3 Key Developments
  118.       5.2.6.4 SWOT Analysis
  119.       5.2.6.5 Key Strategies
  120.     5.2.7 Santen Pharmaceutical Co Ltd (JP)
  121.       5.2.7.1 Financial Overview
  122.       5.2.7.2 Products Offered
  123.       5.2.7.3 Key Developments
  124.       5.2.7.4 SWOT Analysis
  125.       5.2.7.5 Key Strategies
  126.     5.2.8 Zeiss Group (DE)
  127.       5.2.8.1 Financial Overview
  128.       5.2.8.2 Products Offered
  129.       5.2.8.3 Key Developments
  130.       5.2.8.4 SWOT Analysis
  131.       5.2.8.5 Key Strategies
  132.   5.3 Appendix
  133.     5.3.1 References
  134.     5.3.2 Related Reports
  135. 6 LIST OF FIGURES
  136.   6.1 MARKET SYNOPSIS
  137.   6.2 UK MARKET ANALYSIS BY DISEASE STAGE
  138.   6.3 UK MARKET ANALYSIS BY TREATMENT TYPE
  139.   6.4 UK MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
  140.   6.5 UK MARKET ANALYSIS BY HEALTHCARE SETTING
  141.   6.6 UK MARKET ANALYSIS BY MARKET DISTRIBUTION CHANNEL
  142.   6.7 KEY BUYING CRITERIA OF HEALTHCARE
  143.   6.8 RESEARCH PROCESS OF MRFR
  144.   6.9 DRO ANALYSIS OF HEALTHCARE
  145.   6.10 DRIVERS IMPACT ANALYSIS: HEALTHCARE
  146.   6.11 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
  147.   6.12 SUPPLY / VALUE CHAIN: HEALTHCARE
  148.   6.13 HEALTHCARE, BY DISEASE STAGE, 2024 (% SHARE)
  149.   6.14 HEALTHCARE, BY DISEASE STAGE, 2024 TO 2035 (USD Million)
  150.   6.15 HEALTHCARE, BY TREATMENT TYPE, 2024 (% SHARE)
  151.   6.16 HEALTHCARE, BY TREATMENT TYPE, 2024 TO 2035 (USD Million)
  152.   6.17 HEALTHCARE, BY PATIENT DEMOGRAPHICS, 2024 (% SHARE)
  153.   6.18 HEALTHCARE, BY PATIENT DEMOGRAPHICS, 2024 TO 2035 (USD Million)
  154.   6.19 HEALTHCARE, BY HEALTHCARE SETTING, 2024 (% SHARE)
  155.   6.20 HEALTHCARE, BY HEALTHCARE SETTING, 2024 TO 2035 (USD Million)
  156.   6.21 HEALTHCARE, BY MARKET DISTRIBUTION CHANNEL, 2024 (% SHARE)
  157.   6.22 HEALTHCARE, BY MARKET DISTRIBUTION CHANNEL, 2024 TO 2035 (USD Million)
  158.   6.23 BENCHMARKING OF MAJOR COMPETITORS
  159. 7 LIST OF TABLES
  160.   7.1 LIST OF ASSUMPTIONS
  161.     7.1.1
  162.   7.2 UK MARKET SIZE ESTIMATES; FORECAST
  163.     7.2.1 BY DISEASE STAGE, 2026-2035 (USD Million)
  164.     7.2.2 BY TREATMENT TYPE, 2026-2035 (USD Million)
  165.     7.2.3 BY PATIENT DEMOGRAPHICS, 2026-2035 (USD Million)
  166.     7.2.4 BY HEALTHCARE SETTING, 2026-2035 (USD Million)
  167.     7.2.5 BY MARKET DISTRIBUTION CHANNEL, 2026-2035 (USD Million)
  168.   7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  169.     7.3.1
  170.   7.4 ACQUISITION/PARTNERSHIP
  171.     7.4.1

UK Healthcare Market Segmentation

Healthcare By Disease Stage (USD Million, 2026-2035)

  • Early Stage
  • Intermediate Stage
  • Late Stage

Healthcare By Treatment Type (USD Million, 2026-2035)

  • Pharmacological Treatment
  • Surgical Intervention
  • Nutritional Supplements

Healthcare By Patient Demographics (USD Million, 2026-2035)

  • Age Group
  • Gender
  • Socioeconomic Status

Healthcare By Healthcare Setting (USD Million, 2026-2035)

  • Outpatient Clinics
  • Hospitals
  • Home Healthcare

Healthcare By Market Distribution Channel (USD Million, 2026-2035)

  • Direct Sales
  • Online Sales
  • Pharmacies

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories
Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓